Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Axsome Therapeutics, Inc.

< Previous 1 2 3 4 Next >
News headline image
Axsome Therapeutics Recognizes Mental Health Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers ATXI AXSM AZN
News headline image
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
News headline image
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.